2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13D.05 Predictive Impact of Peripheral Blood Lymphocyte Subsets and Serum Markers in First-Line Immunotherapy for ES-SCLC—

EP.13D.05 Predictive Impact of Peripheral Blood Lymphocyte Subsets and Serum Markers in First-Line Immunotherapy for ES-SCLC——A Real-World Study

Back to course

Pdf Summary

The study aimed to evaluate the effectiveness of first-line immune checkpoint inhibitors (ICIs) combined with platinum-containing chemotherapy in treating extensive small cell lung cancer (ES-SCLC). The research was conducted on 278 patients from Shanxi Cancer Hospital using the "CAPTRA-LUNG" database between January 2020 and January 2023. These patients were divided into two groups: one received ICIs with chemotherapy (152 patients), while the other underwent chemotherapy alone (126 patients). Clinical parameters such as tumor and inflammatory markers and lymphocyte subsets in peripheral blood were analyzed.<br /><br />The results indicated that the study group had improved overall survival (OS) and progression-free survival (PFS) compared to the control group, with OS extending to 16.93 months versus 14 months and PFS to 9.17 months versus 5.93 months. The objective response rate (ORR) was 79.5% for the study group, higher than the 64.3% in the control group, making ICIs a beneficial addition to chemotherapy. Durable clinical response (DCR) was 91.7% in the study group versus 85.7% in controls. <br /><br />A multivariate analysis identified neutrophil-to-lymphocyte ratio (NLR), advanced lung index (ALI), and albumin-to-globulin ratio (A/G) as potential biomarkers and risk factors for PFS. Furthermore, implementing chest radiotherapy alongside first-line immunotherapy partially extended PFS, suggesting additional benefits although not statistically significant.<br /><br />Adverse effects were noted, with treatment-related incidents occurring in 51.3% of the study group. Despite this, the safety was considered comparable to conventional treatments. Notably, no peripheral blood lymphocyte subsets evaluated were significant predictors for PFS and OS.<br /><br />Overall, this study highlighted the potential of combining ICIs with platinum-based chemotherapy to enhance treatment outcomes in ES-SCLC patients and suggested some biomarkers for future research.

Asset Subtitle

Xia Song

Meta Tag

Speaker Xia Song

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

immune checkpoint inhibitors

platinum chemotherapy

extensive small cell lung cancer

overall survival

progression-free survival

objective response rate

neutrophil-to-lymphocyte ratio

advanced lung index

albumin-to-globulin ratio

biomarkers